The	O
COVID	O
-	O
19	O
virus	O
has	O
spread	O
rapidly	O
around	O
the	O
world	O
and	O
there	O
are	O
many	O
patients	O
in	O
multiple	O
countries	O
.	O

Great	O
efforts	O
have	O
been	O
made	O
to	O
find	O
effective	O
medications	O
against	O
the	O
COVID	O
-	O
19	O
.	O

This	O
study	O
aims	O
to	O
compare	O
the	O
effectiveness	O
of	O
LINCOCIN	O
®	O
and	O
AZITRO	O
®	O
in	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
associated	O
pneumonia	O
.	O

A	O
total	O
of	O
24	O
hospitalized	O
patients	O
aged	O
between	O
30	O
-	O
80	O
years	O
who	O
were	O
admitted	O
to	O
the	O
Tarsus	O
Medical	O
Park	O
Hospital	O
between	O
February	O
to	O
March	O
2020	O
was	O
included	O
in	O
the	O
study	O
.	O

The	O
patients	O
were	O
divided	O
into	O
LINCOCIN	O
®	O
and	O
AZITRO	O
®	O
treatment	O
groups	O
.	O

Bronchoalveolar	B-UnclearOutcome
-	I-UnclearOutcome
lavage	I-UnclearOutcome
PCR	I-UnclearOutcome
results	I-UnclearOutcome
were	O
compared	O
after	O
treatment	O
.	O

The	O
mean	O
age	O
was	O
58	O
.	O
4	O
±	O
15	O
.	O
4	O
years	O
in	O
the	O
LINCOCIN	O
®	O
group	O
and	O
59	O
.	O
1	O
±	O
16	O
.	O
6	O
years	O
in	O
the	O
AZITRO	O
®	O
group	O
.	O

In	O
the	O
LINCOCIN	O
®	O
group	O
,	O
the	O
rate	O
of	O
males	O
was	O
66	O
.	O
7	O
%	O
and	O
it	O
was	O
58	O
.	O
3	O
%	O
in	O
the	O
AZITRO	O
®	O
group	O
.	O

There	O
were	O
no	O
statistical	O
differences	O
in	O
terms	O
of	O
age	O
and	O
gender	O
between	O
the	O
groups	O
.	O

On	B-TimeFrame
the	I-TimeFrame
6th	I-TimeFrame
day	I-TimeFrame
after	O
starting	O
treatment	O
,	O
negative	O
bronchoalveolar	O
PCR	O
result	O
was	O
83	O
.	O
3	O
%	O
in	O
the	O
LINCOCIN	O
®	O
group	O
and	O
33	O
.	O
3	O
%	O
in	O
the	O
AZITRO	O
®	O
group	O
.	O

The	O
negative	O
bronchoalveolar	O
PCR	O
proportion	O
was	O
significantly	O
higher	O
in	O
the	O
LINCOCIN	O
®	O
group	O
than	O
in	O
the	O
AZITRO	O
®	O
group	O
.	O

LINCOCIN	O
®	O
usage	O
may	O
be	O
more	O
appropriate	O
in	O
the	O
treatment	O
of	O
COVID	O
-	O
19	O
associated	O
pneumonia	O
.	O

Further	O
studies	O
with	O
a	O
large	O
sample	O
size	O
should	O
clarify	O
these	O
results	O
.	O

